a r t I C l e S Sensory systems are immature at birth and undergo experience-dependent maturation during development. In particular, during a critical period (CP) of postnatal development, neuronal circuits are plastic and are easily shaped by sensory experience to reach the mature structural and functional features of the adult 1,2 . In the visual system, experience strongly regulates the maturation of basic properties of the visual cortex (for example, visual acuity), as well as both the opening and closure of the CP 3,4 . Hyperpolarizing and inhibitory GABA signaling through Cl − -permeable ionotropic GABA A receptors is critical for experiencedependent development and plasticity of the visual cortex 2,5-7 . Nevertheless, GABA exerts a depolarizing and mainly excitatory action during early development (until the first or second postnatal week in rodents) 8, 9 . Indeed, immature neurons accumulate Cl − intracellularly through the Na + -K + -2Cl − (NKCC1) co-transporter, resulting in a net depolarizing efflux of Cl − ions after GABA A receptor opening. Conversely, in adolescent and adult animals, it is mostly the co-transporter K + -2Cl − (KCC2) that is expressed, lowering the intracellular Cl − concentration, [Cl] i , and converting GABA A ergic transmission from depolarizing and mainly excitatory to hyperpolarizing and inhibitory.
a r t I C l e S Sensory systems are immature at birth and undergo experience-dependent maturation during development. In particular, during a critical period (CP) of postnatal development, neuronal circuits are plastic and are easily shaped by sensory experience to reach the mature structural and functional features of the adult 1, 2 . In the visual system, experience strongly regulates the maturation of basic properties of the visual cortex (for example, visual acuity), as well as both the opening and closure of the CP 3, 4 . Hyperpolarizing and inhibitory GABA signaling through Cl − -permeable ionotropic GABA A receptors is critical for experiencedependent development and plasticity of the visual cortex 2, [5] [6] [7] . Nevertheless, GABA exerts a depolarizing and mainly excitatory action during early development (until the first or second postnatal week in rodents) 8, 9 . Indeed, immature neurons accumulate Cl − intracellularly through the Na + -K + -2Cl − (NKCC1) co-transporter, resulting in a net depolarizing efflux of Cl − ions after GABA A receptor opening. Conversely, in adolescent and adult animals, it is mostly the co-transporter K + -2Cl − (KCC2) that is expressed, lowering the intracellular Cl − concentration, [Cl] i , and converting GABA A ergic transmission from depolarizing and mainly excitatory to hyperpolarizing and inhibitory.
Although hyperpolarizing and inhibitory GABAergic transmission is a well-known regulator of visual system development and plasticity, and depolarizing GABAergic signaling is fundamental for early physiological maturation of various brain areas 10 , nothing is known about the role of depolarizing GABA in the regulation of cortical plasticity. Here we found that brief interference with depolarizing GABA during early postnatal development prolongs the CP of plasticity in the visual cortex without affecting the overall development of the visual system. This effect is accompanied by changes in the fundamental regulators of plasticity and is rescued by increasing BDNF signaling during depolarizing GABA interference.
RESULTS

Early depolarizing GABA controls CP plasticity
To hamper depolarizing GABA A signaling, we treated rat pups with the NKCC1 inhibitor bumetanide (intraperitoneal (i.p.) administration, 0.2 mg/kg body weight twice a day because of its pharmacokinetics 11 ) from postnatal day (P) 3 to P8 (Fig. 1a) , when NKCC1 is the main K + -Cl − co-transporter in the cerebral cortex ( Supplementary  Fig. 1 ) [8] [9] [10] . Indeed, bumetanide crosses the brain-blood barrier 11 and effectively shifts the reversal potential of GABA (E GABA ), converting GABA A signaling to hyperpolarizing in young rats 10, 12, 13 .
To assess whether perinatal interference with depolarizing GABA affects the time course of the CP for visual cortex plasticity, we used a classical paradigm of experience-dependent plasticity (i.e., 3 days of monocular deprivation (MD)) in bumetanide-and vehicle-treated rats (Fig. 1a) . When performed during the CP (but not in adults), brief MD results in a marked shift of the ocular dominance (OD) of cortical neurons in favor of the nondeprived eye 14 . To define the time course of the sensitive period for plasticity, we performed MD experiments at different ages spanning the normal opening and closing of the CP 15 . To quantify the OD shift, we performed in vivo electrophysiological recordings and measured the contralateral-to-ipsilateral (C:I) visualevoked potential (VEP) ratio (i.e., the ratio of VEP amplitudes recorded by stimulating the contralateral or ipsilateral eye) in bumetanide-and vehicle-treated animals either with MD or left undeprived (nonMD). Baseline binocularity was comparable between nonMD bumetanideand vehicle-treated animals at all tested ages (C:I VEP ratio of 1.5-2 for both groups; Fig. 1c-h) , indicating no specific effect of early bumetanide treatment on the general development of binocularity. The MD experiments indicated that although the onset of CP plasticity was unaffected by bumetanide treatment, its closure was significantly a r t I C l e S delayed (Fig. 1b) . Indeed, OD plasticity rose similarly from P17 to P20 and was maximal at P26 in both bumetanide-and vehicle-treated rats ( Fig. 1c-e) . Conversely, at P35, consistent and significant OD plasticity could be induced in bumetanide-treated animals only (Fig. 1b,f) . Notably, the shift in eye preference of bumetanide-treated animals after MD at P35 involved a depression of responses driven by the deprived eye, an effect that is typical of juvenile-like plasticity 16 ( Supplementary Fig. 2 ). The CP was over in both groups by P45, as plasticity was not significant at either P45 or P75 (Fig. 1b,g,h) .
To strengthen the in vivo data, we assessed the level of in vitro plasticity in the visual system of animals previously treated with bumetanide or vehicle. In particular, we performed field-potential recordings in acute visual cortical slices to assess long-term potentiation (LTP) of layer II/III synaptic responses by theta-burst stimulation (TBS) of the white matter (WM-LTP). This is a classical in vitro model of visual cortical plasticity that is known to undergo an age-dependent developmental decline that correlates closely with the developmental decline in susceptibility to MD in vivo 1, 3, 5 . Consistent with our MD experiments, we found that early GABAergic interference prolonged the CP for WM-LTP induction ( Fig. 2a) (this effect is exemplified in Fig. 2b-g , which shows the average time course of field potential responses before and after TBS at different ages). Whereas both bumetanide-and vehicle-treated animals opened the CP after P17 and showed maximal plasticity at P20-P26 ( Fig. 2a-d) , only bumetanidetreated animals showed significant WM-LTP at P35 (Fig. 2a,e) .
Conversely, neither experimental group showed significant plasticity at older ages (P45 and P75; Fig. 2a,f,g ). Altogether, these results indicate that interfering with depolarizing GABA during early development significantly extends the sensitive period for activity-dependent rearrangements of cortical circuits later in life.
Early bumetanide treatment does not affect overall anatomy
To exclude the possibility that the effect on plasticity was due to defects in the anatomical development of the visual system 10,17 , we investigated the segregation of eye-specific inputs in the dorsal lateral geniculate nucleus (dLGN) and the migration and morphological maturation in the visual cortex of animals perinatally treated with bumetanide or vehicle, as these processes occur early in rat perinatal life 17, 18 . To visualize retinal afferents from both eyes, we performed intravitreal injections of cholera toxin beta (CTB) fragment conjugates of different colors and analyzed coronal dLGN sections at P35 (Fig. 3a) . We found clear segregation of fibers from the two eyes in both bumetanide-and vehicle-treated rats (Fig. 3b) , indicating normal development of retinogeniculate projections.
To investigate the structural development of the visual cortex, we performed in utero electroporation of progenitors of excitatory neurons committed to layer II/III with a plasmid encoding for enhanced GFP (eGFP) at embryonic day (E) 17.5 (Fig. 3c) . This allowed for visualization of neuronal migration and morphological maturation of the neuronal progeny of transfected cells by eGFP fluorescence imaging. Average level of plasticity (quantified as described in the Online Methods) ± s.e.m. derived from experiments performed at different ages (shown in c-h). The level of plasticity was higher in bumetanide-treated animals than in vehicle-treated controls at P35 (**P = 0.009 (P35), post two-way analysis of variance (ANOVA) Holm-Sidak test) but was similar between the two groups at the other time points (P = 0.998 (P17), P = 0.916 (P20), P = 0.999 (P26), P = 0.988 (P45), P = 0.999 (P75)).
(c-h) C:I VEP ratios measured at the ages indicated in vehicle-and bumetanide-treated animals in either nonMD or MD conditions. At all ages, baseline binocularity was superimposable between bumetanide-and vehicletreated rats (post two-way ANOVA Tukey test; P = 0.322 (c), P = 0.972 (d), P = 0.974 (e), P = 0.332 (f), P = 0.872 (g), P = 0.758 (h)). Response to 3 d of MD was also similar throughout development, with the exception of P35. At this age, bumetanide-but not vehicle-treated animals showed an OD shift in favor of the ipsilateral (open eye) as shown by lower C:I VEP ratios (post two-way ANOVA Tukey test, ***P < 0.001). The histograms depict the average values ± s.e.m., and circles represent data from single animals. **P = 0.009.
npg a r t I C l e S
We found that all eGFP-positive neurons reached layer II/III in both bumetanide-and vehicle-treated animals at P35 (Fig. 3d) . Moreover, morphological reconstruction of eGFP-positive neurons did not reveal any significant difference in morphological maturation between the two groups (total branch number, P = 0.502; total branch length, P = 0.646; Fig. 3d and Supplementary Fig. 3 ). Next, to assess the development of GABAergic interneurons, we examined their laminar distribution by immunostaining for the GABA biosynthetic enzyme GAD67 in cortical sections from bumetanide-and vehicle-treated rats at P35. We found no significant differences in the distribution of interneurons between the two groups ( Fig. 3e,f) .
Early bumetanide treatment does not affect visual function
Next we investigated whether bumetanide treatment could affect the overall development of the visual system at the functional level. In general, bumetanide-treated animals developed normally, as their gain of body weight and timing of eye opening were comparable to those of controls ( Fig. 4a and Supplementary Fig. 4) . Moreover, bumetanideand vehicle-injected animals performed equally in learning a visual discrimination task (Prusky visual water box; Fig. 4b ).
Using the same test, we measured visual acuity longitudinally 3 starting from P24 and found no deficits in its maturation in bumetanidetreated animals (Fig. 4c) . We then measured basic physiological parameters in the primary visual cortex using VEP recordings at P35 (i.e., when these parameters reach adult levels in naive animals) 19 . We found that spatial resolution (visual acuity), contrast threshold and VEP amplitude and latency in bumetanide-treated rats were within the normal range and did not differ from those of controls ( Fig. 4d-g ). Thus, briefly interfering with depolarizing GABA during early development prolongs the CP for OD plasticity and WM-LTP into adulthood without affecting the basic anatomical and physiological development of the visual system.
Bumetanide effects are not due to regulation of osmolarity To ensure that the effects of bumetanide treatment on visual cortical plasticity were due specifically to regulation of NKCC1 rather than to side effects of pharmacological treatment, we treated rat pups perinatally (P3-P8) with another NKCC1 inhibitor (furosemide; i.p., 20 mg/kg body weight, twice a day) and assessed the level of plasticity at P35. In fact, furosemide blocks both NKCC1 and KCC2; nevertheless, because of low KCC2 expression at the age of treatment (Supplementary Fig. 1 ), furosemide treatment mimics the effect of the NKCC1-specific blocker bumetanide on chloride regulation under our experimental conditions. Accordingly, we found that furosemidetreated animals displayed higher levels of plasticity than vehicletreated controls at P35, as they responded to brief MD with a robust OD shift and displayed significant WM-LTP in slices (Fig. 5a,b) . These plastic changes were exactly comparable to those observed in bumetanide-injected rats (Fig. 5a,b) , indicating the involvement of early chloride homeostasis in regulating plasticity later in life.
Nevertheless, direct regulation of NKCC1 also results in neuronal shrinkage, as bumetanide and furosemide are diuretics approved by the US Food and Drug Administration that regulate blood osmolarity 20 (Fig. 5c) . Thus, we verified that the effects of bumetanide and furosemide on cortical plasticity are not simply due to an alteration in the volume of the extracellular space 21 . To this aim, we treated rat pups perinatally (P3-P8) with the osmotic diuretic mannitol (i.p., 7.5 g/kg body weight) 20, 22 , which regulates the volume of the extracellular space without affecting NKCC1 activity 20, 22 . Mannitol-treated animals displayed the same levels of plasticity as vehicle-treated npg a r t I C l e S controls, both in vivo and in vitro (Fig. 5a,b) , indicating that bumetanide and furosemide regulate cortical plasticity through modulation of Cl − homeostasis but not cell volume.
Variations in CP regulators accompany bumetanide's effects Next we investigated the possible mechanisms responsible for the higher levels of plasticity at P35 in bumetanide-treated animals. First, as inhibitory GABAergic transmission is a major regulator of closure of the CP 5,7 , we used whole-cell patch-clamp recordings to examine basal GABAergic transmission in visual cortical slices from P35 animals that had been treated perinatally with bumetanide or vehicle. Although the basic membrane properties (membrane resistance, membrane capacitance and membrane resting potential) of layer II/III visual cortical neurons were comparable in the two experimental groups (Supplementary Fig. 5a-c) , the frequency of miniature inhibitory postsynaptic currents (mIPSCs) was drastically reduced in the bumetanide-treated animals (bumetanide, 0.26 ± 0.05 (mean ± s.e.m.) Hz; vehicle, 0.62 ± 0.16 Hz; Fig. 6a ). Conversely, there was no difference in the amplitude (Fig. 6b) or kinetics (τ and rise time; Supplementary Fig. 5d ,e) of these events. Notably, we found no significant effect of perinatal bumetanide treatment on the frequency of miniature excitatory AMPA postsynaptic currents at P35 (bumetanide, 1.40 ± 0.37 Hz, n = 10 cells; vehicle, 1.79 ± 0.41 Hz, n = 9 cells; Student's t test, P = 0.501). Thus we investigated whether we could rescue the persistent OD plasticity of bumetanide-treated animals at P35 by enhancing GABA A ergic transmission with i.p. injection of diazepam 23, 24 during the period of MD in a group of rats treated perinatally with bumetanide ( Supplementary Fig. 6a ). We found that the OD shift was significantly (P = 0.025) mitigated by diazepam infusion (Supplementary Fig. 6b ), indicating that a reduced inhibitory tone accounts in part for the effect of bumetanide on plasticity at P35 and that other regulators of plasticity may also have a role. Thus, as BDNF controls the closure of the CP in the visual system by influencing inhibitory circuits 5,14 , we investigated its expression in bumetanide-and vehicle-treated animals at P35. Using western blot experiments, we found significantly lower levels of BDNF in the visual cortices of bumetanide-treated animals (Fig. 6c) .
Components of the extracellular matrix, such as chondroitin sulfate proteoglycans (CSPGs), also limit experience-dependent plasticity by condensing mostly around parvalbumin (PV)-positive interneurons in the form of perineuronal nets (PNNs) 14, 19, 25 . Therefore, we investigated whether early bumetanide treatment affects PNN development npg a r t I C l e S around PV-positive cells by performing immunostaining using Wisteria floribunda lectin (WFA; to label CSPG glycosaminoglycan chains) and an antibody to PV at P35 (Fig. 6d) . Visual cortical slices derived from bumetanide-treated animals showed a lower PNN density compared to slices from controls ( Fig. 6d,e) . Notably, there was no significant difference in the absolute number of PV-positive cells (Fig. 6e ) or in the density of PV-positive boutons onto pyramidal neurons between bumetanide-and vehicle-treated rats ( Supplementary Fig. 7 ). Nevertheless, double labeling for WFA and PV confirmed that a lower proportion of PV-positive interneurons were surrounded by PNNs in bumetanide-treated animals ( Fig. 6d,e) . Altogether, these findings indicate that the increased plasticity in bumetanide-treated animals at P35 is accompanied by modulation of well-known plasticity brakes, such as GABAergic inhibitory neurotransmission, BDNF and PNNs 4 .
If release of the plasticity brakes were responsible for the higher degree of plasticity in bumetanide-treated animals at P35, then one would expect no difference in the levels of these same plasticity brakes at ages when the potential for plasticity is comparable between bumetanide-and vehicle-treated animals. Therefore, we assessed mIPSCs and BDNF levels at P26 (the peak of plasticity for both bumetanide-and vehicle-treated animals) and mIPSCs, PNNs and BDNF levels at P75 (when the CP is over in both groups). Recordings at P26 and P75 indeed showed no differences in either the frequency or amplitude of mIPSCs between bumetanide-and vehicle-treated animals ( Supplementary Figs. 8a,b and 9a,b) . The frequency of miniature excitatory AMPA postsynaptic currents was also superimposable between the groups (P26, bumetanide, 1.22 ± 0.26 Hz, n = 6 cells; vehicle, 1.36 ± 0.20 Hz, n = 9 cells; Student's t test, P = 0.671; P75, bumetanide, 0.87 ± 0.22 Hz, n = 7 cells; vehicle, 1.05 ± 0.29 Hz, n = 9 cells; Student's t test, P = 0.644). In keeping with the data on mIPSCs, we found comparable levels of BDNF at P26 and P75 in bumetanide-and vehicle-treated animals ( Supplementary  Figs. 8c and 9c) . We assessed the density of PNNs at P75 and again 700 P35
Vehicle (7) Bumetanide (7 The effect of early bumetanide treatment on visual cortical plasticity is due to regulation of cation-Cl − co-transporters rather than the regulation of osmolarity. (a) Average ± s.e.m. of the level of OD plasticity in vehicle-, bumetanide-, furosemide-and mannitol-treated rats at P35. Higher levels of OD plasticity were found in bumetanide-and furosemide-treated animals (post ANOVA Holm-Sidak test: vehicle compared to bumetanide, P < 0.001; vehicle compared to furosemide, P = 0.004) but not in mannitol-injected rats (vehicle compared to mannitol, P = 0.958; bumetanide compared to mannitol, P = 0.009; furosemide compared to mannitol, P = 0.028). The numbers in parentheses are the numbers of animals recorded (nonMD and MD). (b) Average ± s.e.m. and single-slice values (circles) of the level of LTP 30 min after TBS in slices from animals treated as in a. Plasticity was greater in bumetanide-and furosemide-treated animals (post ANOVA Duncan's test: vehicle compared to bumetanide, P < 0.001; vehicle compared to furosemide, P = 0.011) than in vehicle-or mannitol-injected rats (vehicle compared to mannitol, P = 0.784; bumetanide compared to mannitol, P = 0.004; furosemide compared to mannitol, P = 0.039). (c) Average serum osmolarity ± s.e.m. measured 10 min after acute injection of bumetanide at P8. Osmolarity was increased in bumetanide-treated animals in comparison to vehicle controls (Student's t test, *P = 0.024). The histogram depicts the average ± s.e.m., and circles represent data from single animals. *P < 0.05, **P < 0.01, ***P ≤ 0.001. B u m e t a n id e npg a r t I C l e S found no significant changes in the bumetanide-treated animals (P = 0.766; Supplementary Fig. 9d ).
Early DHF co-treatment rescues bumetanide's effects at P35 What are the possible mechanisms that link the effect of early bumetanide treatment with the prolongation of CP plasticity? Depolarizing GABA and BDNF are involved in a positive-feedback reciprocal regulation during early development 26, 27 . In particular, activation of GABA A receptors triggers augmented release of BDNF and enhanced phosphorylation of its receptor TrkB (pTrkB), which in turn reduces the internalization of GABA A receptors from the plasma membrane 26 . Therefore, we hypothesized that perinatal bumetanide treatment may disrupt the positive loop described above, thus reducing BDNF signaling in response to activation of the GABA A receptor. To test this hypothesis, we collected visual cortex samples from pups treated with bumetanide or vehicle perinatally (P3-P8) and systemically challenged at P8 by acute injection of a GABA A receptor agonist (midazolam; i.p., 5 mg/kg body weight; Fig. 7a ). Using quantitative RT-PCR, we found a significant upregulation of Bdnf mRNA expression in vehicle-but not bumetanide-treated animals injected with midazolam (Fig. 7b) .
Next we assessed TrkB activation by western blot analysis with an antibody to pTrkB (Y816) in bumetanide-and vehicle-treated pups after acute midazolam injection. In keeping with the RT-PCR data, we found that GABA A receptor activation enhanced TrkB phosphorylation in vehicle-but not bumetanide-treated pups (Fig. 7c) . Together these results suggest that early interference with depolarizing GABA by bumetanide treatment impairs both the synthesis and release of BDNF.
To investigate whether the perinatal decrease in BDNF signaling mediated the effects of early bumetanide treatment on visual cortical plasticity later in life, we performed a rescue experiment by increasing BDNF signaling concomitant to bumetanide treatment. In particular, we injected bumetanide together with the BDNF mimetic drug 7,8-dihydroxyflavone (DHF; i.p., 5 mg/kg body weight 28 from P3 to P8; Fig. 7d) , which induces TrkB phosphorylation in the cortex in vivo 28 . Infusion of DHF and bumetanide together during early development normalized the level of plasticity at P35 both in vivo (Fig. 7e,f) and in vitro (Fig. 7g,h) . Notably, DHF treatment per se did not interfere with plasticity, as WM-LTP induction at P26 in rats treated perinatally with DHF or vehicle showed comparable levels of plasticity (Supplementary Fig. 10) . Notably, treatment of DHF together with bumetanide also rescued inhibitory GABAergic transmission (Fig. 8a) , BDNF expression (Fig. 8b) and PNNs (Fig. 8c) . Thus, disruption of positive feedback regulation between depolarizing GABA and BDNF during early development accounts for the effects of early bumetanide treatment on the plasticity of the visual system later in life.
DISCUSSION
Depolarizing GABA also controls CP plasticity Hyperpolarizing and inhibitory GABA has a major role in regulating CP plasticity in the visual cortex [5] [6] [7] 14 . In particular, opening of the CP requires reaching a threshold level in the development of GABAergic inhibition 6 , whereas complete development of GABAergic inhibition leads to the closure of the time window of maximal plasticity 5, 7 . Unlike in adults, GABA depolarizes neuronal cells during early development, representing the main excitatory drive for immature cortical networks 8 . Consequently, depolarizing GABA has been implicated in a series of developmental processes, including neuronal migration and morphological differentiation, as well as synapse maturation in the cortex 8, 9 . To our knowledge, we report for the first time a key role for early depolarizing GABA in the long-lasting control of the plasticity of neuronal circuits.
To interfere with early GABA action, we used systemic administration of the NKCC1 inhibitor bumetanide, with timing and doses that are effective in abolishing GABA-induced depolarization 10 . We evaluated the plasticity of cortical circuits using two independent measures, Treatment with another NKCC1 inhibitor, furosemide, yielded a similar effect on CP plasticity at P35. Nevertheless, as changes in the volume of the extracellular fluid can potently affect brain excitability 21 , we tested whether the effects of NKCC1 inhibition were secondary to alterations of cell volume described after diuretic treatment [20] [21] [22] rather than regulation of Cl − homeostasis. We found that early treatment with the osmotic diuretic mannitol-which does not regulate NKCC1 activity-failed to replicate the effect on plasticity. Altogether, our experimental evidence adds to the vast literature on the role of GABA in the control of visual cortical plasticity, indicating that not only hyperpolarizing but also depolarizing GABA has an important role.
Early depolarizing GABA controls plasticity specifically The decline of susceptibility to MD and WM-LTP induction temporally correlates with the development of visual functions, assessed in terms of the maturation of visual acuity 1, 5 . In a number of studies, manipulations affecting the time course of the CP also affected the overall development of the visual system. For example, rearing animals in darkness constrains the visual system in an immature state with decreased visual acuity, which is coupled to a prolongation of the window of susceptibility to MD and WM-LTP 15, 29 . Conversely, manipulations leading to precocious closure of the CP for plasticity, such as environmental enrichment 3 , administration of IGF1 (ref. 30) or BDNF overexpression 5, 29 , also cause accelerated cortical development (i.e., early maturation of visual acuity). Thus, the physiological development and plasticity of the visual cortex have been classically considered as two strongly intermingled processes, with maturation of visual function being ineludibly linked to a waning of the potential for experience-dependent modifications 1 . Our results indicate that at least under certain conditions, the two processes may be regulated independently, as has been seen for other individual response properties in developing cortical networks 31, 32 . Indeed, we found that early GABA interference prolonged the time npg a r t I C l e S window for plasticity while leaving the overall anatomical and physiological maturation of the visual system unaffected. We documented clear segregation of retinogeniculate fibers in the dLGN, no alteration in migration or morphological maturation of layer II/III pyramidal neurons and normal laminar distribution of interneurons in the visual cortex. Visual acuity, binocularity, contrast threshold, VEP amplitude and latency were within the normal range at P35, the same age at which consistent and significant plasticity could be induced in bumetanide-treated animals only. The combined regulation of CP plasticity and overall visual system development found in previous studies (i.e., dark rearing from birth 15 , BDNF overexpression in transgenic mice 5, 29 , environmental enrichment from birth 3 or IGF-1 administration after weaning 30 ) may depend on the fact that these long-lasting experimental protocols set in motion a number of different pathways acting in parallel to regulate physiological maturation and simultaneously delimit experience-dependent plasticity. Conversely, we found that early and selective NKCC1 inhibition left a specific mark on developing cortical circuits, affecting only the duration of the plasticity window.
At the functional level, the dissociation between CP plasticity and overall visual system development may be convenient, as cortical networks may remain customizable by experience even at the completion of the period of physiological maturation. This idea is consistent with the robust plasticity described in fully mature mice after prolonged MD 14 .
The absence of gross neuroanatomical defects in bumetanidetreated animals is seemingly in contrast with the reported alteration in cortical neuron morphology after treatment with bumetanide starting from the embryonic stage to the first postnatal week 10 . This discrepancy may be due to a longer time period of the previous treatment (E15-P7) in comparison to our manipulation (P3-P8). Moreover, treatment from E15 to P7 includes the time of delivery. As delivery is associated with a marked shift of GABA action from depolarizing to hyperpolarizing 33, 34 , part of the discrepancy with our results could depend on the fact that manipulation from E15 to P7 includes a time period in which GABA is not depolarizing.
Early depolarizing GABA and BDNF exert long-term control of CP regulators
Critical-period plasticity in the visual cortex is controlled by fundamental regulators such as inhibitory GABAergic transmission, BDNF and the extracellular matrix 14 . In particular, GABAergic inhibition and PNNs are considered to be classical plasticity brakes 4 because their downregulation in adulthood effectively restores the sensitivity of cortical networks to MD and WM-LTP 7, 25, 35 . In keeping with this idea, the high plasticity of bumetanide-treated rats at P35 was accompanied by a decrease in inhibitory neurotransmission, the number of PNNs and BDNF levels. Notably, we found that the GABA inhibitory tone was involved in the higher OD plasticity of bumetanide-treated rats at P35, as enhancing GABAergic transmission with diazepam significantly dampened the response to MD. We also found no difference in the expression of these brakes at ages when plasticity was the same between bumetanide-and vehicle-treated animals (P26, peak of the CP; and P75, adulthood). The amplitude and frequency of GABAergic events that we recorded at all ages were lower than those reported in other studies using access resistances lower than ours [36] [37] [38] [39] , although the frequency that we report here is in agreement with a recent study using an access resistance similar to ours 32 .
Besides their coordinated effect on visual cortex plasticity, GABAergic transmission, BDNF and the extracellular matrix also interact with one another in the control of visual cortex development 5, 25, 40 . For example, activation of GABA A receptors by depolarizing GABA during early development triggers the synthesis and release of BDNF 26, 27 . The consequent activation of TrkB, in turn, promotes cell-surface expression of GABA A receptors, leading to a positive feedback loop 26 . We found that disruption of this positive loop was a key event in the plasticizing effects of bumetanide treatment. Indeed, BDNF signaling downstream of GABA A receptor activation was significantly impaired in bumetanide-treated pups, and the long-term consequences of NKCC1 inhibition (i.e., increased plasticity at P35) were counteracted by TrkB activation through DHF treatment. Notably, restoration of a normal closure of the CP by early treatment with DHF and bumetanide together was also accompanied by recovery of the normal levels of GABAergic inhibition, PNNs and BDNF, npg a r t I C l e S confirming the tight correlation between functional plasticity and these plasticity brakes. However, DHF treatment per se did not alter cortical plasticity. Altogether, these findings demonstrate that the loop between depolarizing GABA and BDNF during early development regulates the widely described interaction between hyperpolarizing GABA, BDNF and PNNs, which are major regulators of CP plasticity later in life.
Mechanisms of CP regulation by early depolarizing GABA Our data demonstrate that BDNF signaling is a crucial mediator of the effects of early depolarizing GABA on cortical inhibition and plasticity later in development. But what are the mechanisms that may account for the long-term, plasticizing effects of transient interference with depolarizing GABA?
At least three different mechanisms (working alone or in combination) can be hypothesized. First, depolarizing GABA signaling might directly 41 or indirectly (through BDNF 26, 27 ) promote the subsequent maturation of inhibitory circuitry necessary for the closure of the CP 5, 7 . Nevertheless, this hypothesis seems unlikely. As GABAergic inhibition is also necessary for the opening of the CP, if the above hypothesis were true, one would expect a temporal shift of the whole CP rather than its mere prolongation, as we found in the current study.
Second, spontaneous activity (before the onset of visual experience) and visually evoked discharges represent a continuum that acts to determine and instruct visual circuit development and plasticity 8, 42 . By definition, the CP is a phase of heightened sensitivity to environmental stimuli during which cortical networks are customized by visual experience 14 . When network activity is reduced, such as in dark rearing, the visual system reacts with an extension of the CP to prolong the effective time window during which visual experience can instruct circuit refinement 15 . In this context, a precocious reduction of GABA-mediated excitation during early development may trigger extended plasticity of the visual cortex to compensate for the early loss of wiring instructions coded by the spontaneous activity patterns. The specific effect of early bumetanide treatment on the closure (and not the opening) of the CP, together with the retention of a juvenile-like plasticity at P35, would favor this hypothesis.
A third possible explanation for the long-term effects of early GABA interference resides in epigenetic mechanisms 43, 44 . Classic experiments have shown that early environmental experiences (such as levels of early maternal care) influence adult behavior by modifications in chromatin structure 45 . Thus, we speculate that transient interference with GABA-mediated excitation may leave persistent marks on specific classes of cortical neurons, reverberating on altered function and structure (i.e., reduced inhibitory transmission and reduced PNN) later in life. These epigenetic changes could display their effects at specific developmental stages (i.e., P35) with no apparent impact on the initial, default developmental trajectory of plasticity and its regulators.
Therapeutic perspective
Bumetanide is a drug approved by the US Food and Drug Administration that has been used extensively in the past as a loop diuretic and is used currently to treat heart failure and respiratory disorders in infancy 20 . Notably, because of its ability to inhibit the brainspecific transporter NKCC1, bumetanide has been proposed as a promising candidate to treat brain diseases 46 on the basis of studies in animal models 12, 34, 46 and recent clinical trials [46] [47] [48] . However, the use of this drug in neonates has been partially questioned 10, 49, 50 because of the key role of depolarizing GABA during early development 8 .
Our data similarly suggest possible long-term consequences of NKCC1 inhibition during early development. Our study also sheds light on the existence of therapeutic windows for pharmacological interventions aimed at prolonging CP plasticity without affecting overall neuronal circuit development 46 . 
METHODS
Methods
ONLINE METHODS
Animal treatment. All procedures were approved by Istituto Italiano di Tecnologia licensing, the Italian Ministry of Health and EU guidelines (Directive 2010/63/EU). Long Evans rats were housed at 21 °C, in a 12-h light, 12-h dark cycle and given food and water ad libitum. Female and male littermates were injected i.p. twice a day, from P3 to P8, with bumetanide (0.2 mg/kg body weight; Sigma), furosemide (20 mg/kg body weight; Sigma), DHF (5 mg/kg body weight; Sigma) or vehicle (DMSO, 0.04% in physiological solution) and once a day with mannitol (7.5 g/kg body weight; Sigma). For the midazolam experiments, vehicle-and bumetanide-treated pups received one injection of midazolam at P8 (i.p., 5 mg/kg body weight; IBI). MD was performed as described 19 . A subset of rats treated perinatally with bumetanide were monocularly deprived at P35 and treated daily with diazepam (2 mg/kg body weight, i.p 24 ; kindly provided by Roche) to enhance GABA A ergic inhibition, starting 4 h before eyelid suture. Rat body weights were monitored twice a day.
In vivo electrophysiology. Rats were anesthetized with Hypnorm/Hypnovel (in water; 0.375 ml/kg body weight; VetaPharma, UK), and the skull overlying the binocular visual cortex was drilled on one side. A glass micropipette (2 MΩ) filled with NaCl (3 M) was mounted on a motorized micromanipulator and inserted into the binocular visual cortex. VEPs were recorded from three to four penetrations per animal, and the electrode was positioned at 100-and 400-µm depth within the cortex. Electrical signals were amplified (10,000-fold), bandpass filtered (0.3-100 Hz), digitized and averaged in synchrony with the stimulus contrast reversal. Analysis of the amplitude of VEP responses was performed blind to animal treatment. Visual stimuli were gratings of various spatial frequencies and contrast generated by a VSG2/5 card (Cambridge Research Systems, Rochester, UK) on a display (Sony Multiscan G500; mean luminance, 15 cd/m 2 ) positioned 20-30 cm from the rat's eyes to include the central visual field (110 × 85° of visual angle).
Steady-state VePs: visual acuity and contrast threshold. VEP recordings in steady-state mode were used to measure spatial resolution and contrast threshold. The visual response was measured as the amplitude (µV) of the second harmonic of the stimulation frequency (4 Hz), calculated after Fourier analysis of the signal. Visual acuity was assessed after presentation of gratings of variable spatial frequencies (90% contrast). Visual acuity was determined by extrapolation to 0 V of the linear regression through the four to six points closest to the noise level in a curve where VEP amplitude was plotted against the log spatial frequency. In the same temporal frequency (4 Hz), we analyzed contrast threshold in response to 0.07 cycles per degree (c/deg) gratings. Contrast threshold was taken as the lowest contrast that evoked a VEP response greater than the mean value of the noise. 10 phosphocreatine Na 2 + ; 2 Mg 2+ ATP; and 0.25 Na 2 GTP (~300 mOsm, pH 7.4). The membrane resting potential was measured immediately after whole-cell access at 0 current. Criteria for accepting a recording included input resistance >200 MΩ and access resistance <25 MΩ, with a maximal variation of 20%. Capacitance, input and access resistance were measured online with Clampex 10.2. For mPSCs, the holding potential was set at −70 mV, and gap-free recordings were performed for 5 min in tetrodotoxin (0.2 µM; Tocris) to establish the baseline of mPSC frequency. Then, 6,7-dinitroquinoxaline-2,3-dione (DNQX) (20 µM; Tocris) was bath applied for 5 min to isolate mIPSCs. Application of both bicuculline methiodide (25 µM; Sigma) and DNQX abolished all mPSCs. Miniature excitatory postsynaptic current (mEPSC) frequency was calculated by subtracting the frequency of mIPSCs from the frequency of baseline mPSCs. Data, filtered at 0.1 Hz and 5 kHz and sampled at 25 kHz, were acquired with a patch-clamp Multiclamp 700 amplifier and analyzed using pClamp 10.2 software. All chemicals were purchased from Sigma, unless otherwise specified. labeling and analysis of retinogeniculate axons. Labeling of retinogeniculate axons was performed as described previously 18, 51 . Rats received an intravitreal injection of CTB conjugated with Alexa Fluor 488 (10 mg/ml; Invitrogen) into the left eye and CTB-Alexa Fluor 594 (10 mg/ml; Invitrogen) into the right eye 2 d before perfusion. Animals were perfused transcardially with 4% paraformaldehyde (PFA) in 0.1 M phosphate buffer. Brain coronal sections were cut on a freezing microtome (50-µm thick) and collected in a serial order through the entire thalamus.
CTB labels were examined with a Leica confocal microscope using a 10× objective (air, numerical aperture (NA) 0.4). For each animal, we acquired the five largest sections through the middle of the dLGN 18 . The relative areas occupied by the ipsilateral and contralateral projections were calculated by dividing the average of the five ipsilateral or contralateral areas by the average of the five total dLGN areas. To determine the extent of overlap between ipsilateral and contralateral projections to the same dLGN, the ipsilateral and contralateral areas were measured, and their sum was subtracted from the total dLGN area and expressed as a percentage of it. tripolar in utero electroporation of the visual cortex. Tripolar in utero electroporation of the visual cortex was performed as described previously 52 . Timed-pregnant Long Evans rats were anesthetized at E17.5 with isoflurane (induction, 3.5%; surgery, 2.5%), and uterine horns were exposed by laparotomy. Expression vectors (pCAG-IRES-eGFP; 1.5 µg/µl in water) and Fast Green dye (0.3 µg/µl; Sigma, St. Louis, MO) were injected (5-6 µl) through the uterine wall into one of the embryo's lateral ventricles by a 30-G needle. While the embryo's head was carefully held between standard forceps-type circular electrodes (10-mm diameter; positive poles; Nepa Gene, Chiba, Japan), a third electrode npg (7 mm × 6 mm × 1 mm; negative pole) was positioned on the back of the embryo's head. Five electrical pulses (amplitude, 50 V; duration, 50 ms; intervals, 100 ms) were delivered with a square-wave electroporation generator (CUY21EDIT, Nepa Gene). Uterine horns were returned into the abdominal cavity, and embryos continued their normal development.
Slice histology. P35 rats were transcardially perfused with 4% PFA in 0.1 M phosphate buffer (PB), pH 7.4. Brains were cut coronally (80-µm thick) with a freezing microtome. Free-floating slices were permeabilized and blocked with PBS containing 0.3% Triton X-100, 10% normal goat serum (NGS; Jackson ImmunoResearch) and 0.2% bovine serum albumin (BSA) and then incubated with NeuN antibody (mouse anti-NeuN, 1:1,000, Millipore, #MAB377) followed by Alexa-568 fluorescent secondary antibody (1:600, Invitrogen, #A11031).
confocal image acquisition and analysis. For high-magnification images of the cell morphology of eGFP-transfected neurons, 80-µm-thick z stacks were acquired with a 20× objective (oil, NA 0.7), and z series were projected to two-dimensional representations followed by neurite tracing and quantification with the NeuronJ plugin of ImageJ software.
Immunohistochemistry. Animals were deeply anesthetized and perfused with 4% PFA in 0.1 M PB, pH 7.4. Brains were cut coronally with a freezing microtome. For PV immunostaining, free-floating sections were blocked for 2 h at room temperature with 10% NGS and 0.3% Triton X-100 in PBS. Slices were incubated overnight at 4 °C with parvalbumin-specific primary antibody (guinea pig polyclonal, #195004, 1:1,000, Synaptic Systems 53 ), followed by donkey anti-guinea pig DyLight-488 (1:200, Jackson ImmunoResearch). For PNN labeling, we used lectin WFA (#L1516-2mg) 25 . The blocking solution contained 3% BSA in PBS, and biotinylated WFA (1% BSA in PBS; 1:100, Sigma) was applied overnight at 4 °C. WFA was revealed with 1 h of incubation in Cy3-conjugated ExtrAvidin (1:500, Sigma). For GAD67 immunostaining, the blocking solution contained 10% NGS, 3% BSA and 0.3% Triton X-100 in PBS. Anti-GAD67 (mouse monoclonal, #MAB5406, 1:500, Millipore 54 ) was applied overnight at 4 °C. The signal was revealed with 1 h of incubation in biotin-conjugated secondary antibody and streptavidin-conjugated fluorophore (Alexa 594, 1:500, Life Technologies).
For immunohistochemistry quantifications, PNNs and PV-positive cells were counted blind to treatment on a fluorescence microscope using a 40× objective (oil, NA 1.25) and StereoInvestigator software (Microbrightfield). Cells were counted in vertical columns (250-µm width) spanning the entire thickness of the primary visual cortex. Six to eight sections were analyzed for each experimental animal. For the colocalization analysis, we calculated the percentage of PV-positive cells surrounded by PNNs. Counting of GAD67-positive cells was performed on three sections for each experimental animal. For each section, images of the visual cortex were acquired with a 20× objective (air, NA 0.5) by a Zeiss AxioObserver z1 microscope with a motorized stage. Acquisitions were automatically performed using the MosaiX and Z-Stack modules of the Zeiss AxioVision software (v4.3.1). Five z series for each image were projected to two-dimensional representations. Cells were separately counted in layers II/III, IV and V/VI of the primary visual cortex with Adobe Photoshop software (200 µm × 600 µm counting frame). Only cells larger than 5 µm with a clearly visible nucleus were counted. For the counting of PV-positive boutons, confocal images from layer II/III of the visual cortex were acquired with a 60× objective (oil, NA 1.4) using a confocal microscope (A1, Nikon). Two fields for each animal were analyzed. Perisomatic PV-positive boutons around putative cell somas were counted using NIS-Elements AR software and are expressed as the number of boutons per cell soma in a single (largest) focal section, as described previously 55 . For each animal, bouton densities from at least 15 cell somas were averaged. For all experiments, data acquisition and quantification were performed blind to the treatment.
eye-opening observations. From P11, rat pups were inspected for eye opening twice daily. Eye opening was defined as the initial break in the membrane sealing the lids of both eyes.
Prusky water maze. Rats were tested blind to treatment in the visual water task as described previously 3, 19 . The apparatus consisted of a trapezoidal-shaped pool filled with opaque water and partially divided at one end into two arms by a divider.
Visual stimuli consisted of gratings or gray fields generated with two computer monitors and placed at the end of each arm. A hidden platform was placed below the grating. During the learning phase (P17 or P19 to P23 or P24), visual stimuli consisted of gratings of low spatial frequency (0.1 cycles/degree). Animals were trained to associate the stimulus grating with the submerged platform. We report the performance in the learning the task as the percentage of correct choices over the training sessions.
Behavioral assessment of visual acuity was performed from P24 to P32. The limit of discrimination was estimated by increasing the spatial frequency of the grating until performance fell below 70% accuracy. For each rat, distinct sessions of visual acuity estimation were run three times a day every other day. A frequency-of-seeing curve was constructed from the total data, and the spatial frequency corresponding to 70% accuracy was taken as the acuity value 19 .
Serum collection and osmolarity measurement. Ten minutes after a single bumetanide i.p. injection at P8, rat pups were anesthetized deeply, and blood collection was performed by cardiac puncture. Samples were centrifuged (Centrifuge 5417R, Eppendorf), and the osmolarity of the recovered serum was estimated by a vapor pressure osmometer (Wescor).
western blot analysis. Western blot experiments were performed as described previously 3, 19 . Rats were anesthetized deeply, and the primary visual cortex was dissected out. Proteins were extracted with lysis buffer (1% Triton X-100, 10% glycerol, 20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 10 mM ethylenediaminetetraacetic acid (EDTA), 0.1 mM Na 3 VO 4 , 1 µg/ml leupeptin, 1 µg/ml aprotinin and 1 mM phenylmethylsulfonyl fluoride (PMSF)). Protein extracts (10-50 µg per lane, depending on the protein) were boiled for 5 min at 100 °C, loaded on Bis-Tris 4-12% precast gels (Bio-Rad), separated using sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) (1 h at 200 V) and blotted onto a nitrocellulose membrane (Bio-Rad). Blots were blocked using a solution of 4% milk and 0.2% Tween-20 in Tris-buffered solution (TBS) for 2 h at room temperature. The primary antibodies to NKCC1 (mouse monoclonal, #T4, 1:500, DSHB 56 ), KCC2 (rabbit polyclonal, #07-432, 1:1,000, Millipore 56 ), BDNF (rabbit polyclonal, # sc-546, 1:200, Santa Cruz), pTrkB (rabbit, 1:1,000, kindly provided by M.V. Chao) and TrkB (mouse monoclonal, #610101, 1:1,000, BD Biosciences 57 ) were applied overnight at 4 °C in blocking solution containing 2% milk and 0.1% Tween-20 in TBS. Blots were then incubated with 1:20,000 horseradish peroxidase (HRP)-conjugated secondary antibodies (Jackson ImmunoResearch, West Grove, PA) for 2 h at room temperature to reveal the signal in chemiluminescence (ECL) using the luminol/enhancer system (Immun-Star Western C, Bio-Rad) and autoradiography films (HyperFilm, GE Healthcare). In selected experiments, we used secondary antibodies conjugated with infraredemitting dyes (rabbit IRDye 800CW, 1:20,000 or mouse IRDye 680RD, 1:20,000, Li-Cor Biosciences; incubated for 1 h at room temperature) and revealed the signal with the Odyssey scanner system (Li-Cor Biosciences). Films or filters were scanned using an Epson scanner (Epson) or an Odyssey IR (infrared) scanner (Li-Cor), respectively. Densitometry analysis of films was done with ImageJ, and analysis of filters was done with Image Studio software version 3.1 (Li-Cor), respectively. As an internal standard, all blots were probed for α-tubulin (mouse monoclonal, 1:20,000, Sigma). For the pTrkB signal, the total TrkB expression was used for standardization.
Quantitative Rt-PcR. Visual cortices were dissected 3 h after midazolam treatment in P8 rat pups. Quantitative RT-PCR was performed as described previously 54 . Total RNAs were extracted (TRIzol reagent, Invitrogen), treated with DNase and purified with the RNeasy Mini Kit (Qiagen, USA). cDNA was synthesized from RNAs (2 µg) using SuperScript VILO (Invitrogen Life Technologies, USA). Quantitative real-time PCR was performed using a CFX 384 thermal cycler with real-time detection of fluorescence (Bio-Rad). Individual PCR reactions were conducted using the MESA GREEN quantitative PCR (qPCR) kit (Eurogentec SA, Belgium). Primers (Sigma) were designed on different exons to avoid amplification of genomic DNA. Glyceraldehyde 3-phosphate dehydrogenase (Gapdh) was used as a standard for quantification. The primer sequences used were as follows: Bdnf exon 9a, forward ATGGGCCACATGCTGTCCCCG, reverse TTCTGGTC CTCATCCAGCAGC; Gapdh, forward ACTAACCGTTGTCCCAATCT, reverse CTCTTGCTCTCAGTATCCTT. Each PCR cycle consisted of denaturation for 10 s at 94 °C, annealing for 20 s at 60 °C and extension for 30 s at 72 °C. 
